CA1261748A - Methode de traitement de l'immunoglobuline intraveineuse - Google Patents

Methode de traitement de l'immunoglobuline intraveineuse

Info

Publication number: CA1261748A
Authority: CA; Canada
Prior art keywords: immune globulin; intravenous immune; approximately; hour; lyophilized
Prior art date: 1988-01-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000556024A

Other languages

English (en)

Inventor

Alan I. Rubinstein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Southern California USC

Original Assignee

University of Southern California USC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-07

Filing date

1988-01-07

Publication date

1989-09-26

1988-01-07 Application filed by University of Southern California USC filed Critical University of Southern California USC

1988-01-07 Priority to CA000556024A priority Critical patent/CA1261748A/fr

1989-09-26 Application granted granted Critical

1989-09-26 Publication of CA1261748A publication Critical patent/CA1261748A/fr

Status Expired legal-status Critical Current

Links

102000018358 immunoglobulin Human genes 0.000 title claims abstract description 66
108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 65
238000001990 intravenous administration Methods 0.000 title claims abstract description 49
238000000034 method Methods 0.000 title claims abstract description 41
238000010438 heat treatment Methods 0.000 claims abstract description 25
208000006454 hepatitis Diseases 0.000 claims abstract description 22
241000700605 Viruses Species 0.000 claims abstract description 21
208000030507 AIDS Diseases 0.000 claims abstract description 11
231100000283 hepatitis Toxicity 0.000 claims description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
239000008223 sterile water Substances 0.000 claims description 9
230000000694 effects Effects 0.000 claims description 5
229960002520 hepatitis vaccine Drugs 0.000 claims description 3
229940124718 AIDS vaccine Drugs 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 19
238000004108 freeze drying Methods 0.000 abstract description 4
239000000126 substance Substances 0.000 abstract description 4
239000003085 diluting agent Substances 0.000 abstract description 3
230000002163 immunogen Effects 0.000 abstract description 2
230000004952 protein activity Effects 0.000 abstract 1
108010074605 gamma-Globulins Proteins 0.000 description 11
239000000523 sample Substances 0.000 description 9
241000283973 Oryctolagus cuniculus Species 0.000 description 6
230000005540 biological transmission Effects 0.000 description 6
241000724709 Hepatitis delta virus Species 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
208000002672 hepatitis B Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
208000005331 Hepatitis D Diseases 0.000 description 2
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000005686 Serum Globulins Human genes 0.000 description 2
108010045362 Serum Globulins Proteins 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
208000029570 hepatitis D virus infection Diseases 0.000 description 2
238000000760 immunoelectrophoresis Methods 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
229940010675 intramuscular immunoglobulin Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
241000714195 Aids-associated retrovirus Species 0.000 description 1
201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
108010032597 Cohn fraction II Proteins 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
229940033330 HIV vaccine Drugs 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000950638 Symphysodon discus Species 0.000 description 1
208000016349 X-linked agammaglobulinemia Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000004848 nephelometry Methods 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA000556024A 1988-01-07 1988-01-07 Methode de traitement de l'immunoglobuline intraveineuse Expired CA1261748A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000556024A CA1261748A (fr)	1988-01-07	1988-01-07	Methode de traitement de l'immunoglobuline intraveineuse

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000556024A CA1261748A (fr)	1988-01-07	1988-01-07	Methode de traitement de l'immunoglobuline intraveineuse

Publications (1)

Publication Number	Publication Date
CA1261748A true CA1261748A (fr)	1989-09-26

Family

ID=4137200

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000556024A Expired CA1261748A (fr)	1988-01-07	1988-01-07	Methode de traitement de l'immunoglobuline intraveineuse

Country Status (1)

Country	Link
CA (1)	CA1261748A (fr)

1988
- 1988-01-07 CA CA000556024A patent/CA1261748A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2008-01-07	MKEX	Expiry

Publication	Publication Date	Title
US4721777A (en)	1988-01-26	Process for the virus-inactivation of immunoglobulin
EP0094611B1 (fr)	1986-06-11	Procédé de traitement par la chaleur du plasma ou de fractions du plasma et compositions ainsi obtenues
Piet et al.	1990	The use of tri (n‐butyl) phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation
Horowitz et al.	1992	Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma
Stiehm	1979	Standard and special human immune serum globulins as therapeutic agents
Gelfand	2006	Differences between IGIV products: impact on clinical outcome
CZ190292A3 (en)	1993-01-13	Virus inactivated blood product
US4490361A (en)	1984-12-25	Virus inactivating heat treatment of plasma fractions
JPH04145031A (ja)	1992-05-19	分泌型免疫グロブリンａ製剤の製造法
JPH0438730B2 (fr)	1992-06-25
JPH0662436B2 (ja)	1994-08-17	静注用免疫グロブリン製剤の製造方法
US5075425A (en)	1991-12-24	Process for the preparation of a pharmaceutical which contains igg, iga and igm and can be administered intravenously
Hovi et al.	1995	Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy
JP2506370B2 (ja)	1996-06-12	増殖性濾過性病原体の不活化法
Omar et al.	1996	Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation
US4845199A (en)	1989-07-04	Process for heat treating chemically unmodified gamma-globulin
CA1261748A (fr)	1989-09-26	Methode de traitement de l'immunoglobuline intraveineuse
Prince et al.	1985	Inactivation of the hutchinson strain of non‐A, non‐B hepatitis virus by combined use of β‐propiolactone and ultraviolet irradiation
JPH0825903B2 (ja)	1996-03-13	γ―グロブリン含有水溶液
WO1987005220A1 (fr)	1987-09-11	Procede de traitement de gammaglobuline
French	1952	The pyrogenic effect of the influenza-mumps group of viruses in the laboratory rabbit.
JPS62289523A (ja)	1987-12-16	静脈投与用免疫グロブリンの加熱処理方法
Gao et al.	1993	Enhancement in the safety of immune globulins prepared from high-risk plasma
Buxmann et al.	2012	An open-label, randomized efficacy and safety trial of subcutaneous and intramuscular BT088 (Fovepta) human hepatitis B immunoglobulin in neonates of HBV-carrier mothers.
McCue	1989	Changes in therapeutic proteins caused by preparation techniques